[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100125416":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":48,"collaborators":50,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":7,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":7,"studyType":67,"phases":7,"briefSummary":68,"conditions":69,"keywords":74,"overallStatus":33,"whyStopped":7,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"University of Colorado, Denver","OTHER",null,[9,12,15,17],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"immunohistochemistry staining method","Laboratory test",{"type":6,"name":13,"description":14,"armGroupLabels":7,"otherNames":7},"laboratory biomarker analysis","Laboratory Test",{"type":6,"name":16,"description":14,"armGroupLabels":7,"otherNames":7},"sputum cytology",{"type":18,"name":19,"description":14,"armGroupLabels":7,"otherNames":7},"PROCEDURE","biopsy",[21],{"name":22,"affiliation":5,"role":23},"York E. Miller, MD","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":7,"email":29},"Brandi Kubala","CONTACT","303-724-1657","brandi.kubala@cuanschutz.edu",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"University of Colorado Cancer Center at UC Health Sciences Center","RECRUITING","Aurora","Colorado","80045","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-104.83192,39.72943,{"lat":43,"lon":42},[46],{"name":47,"role":27,"phone":28,"phoneExt":7,"email":7},"Clinical Trials Office - University of Colorado Cancer Center",{"type":49,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[51],{"name":52,"class":53},"National Cancer Institute (NCI)","NIH","100125416","biomarkers-in-patients-with-respiratory-tract-dysplasia-or-lung-cancer-head-and-neck-cancer-or-aerodigestive-tract-cancer-and-in-normal-volunteers-100125416",false,"NCT00900419","Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers","Biomarkers and Dysplastic Respiratory Epithelium","Inclusion Criteria:\n\n* Diagnosis of extensive and severe dysplasia of the respiratory epithelium\n* Those without dysplasia of the respiratory epithelium\n\n  * Recruited from the SPORE Tissue Procurement Screening Project or by private or academic physicians (for patients with moderate or severe dysplasia)\n* Survived 1 or more aerodigestive system carcinoma for ≥ 1 year\n* Completely resected stage I non-small cell cancer\n* Undergoing any of the following procedures:\n\n  * Routine panendoscopy for patients with head and neck cancer\n  * Resection of a bronchogenic carcinoma\n  * Bronchoscopy for diagnosis or staging of suspected lung cancer\n  * Subsequent bronchoscopy for surveillance or monitoring of response to endobronchial treatment in patients with prior high-grade dysplasia or worse\n  * No asthma\n  * No lung disease\n  * No respiratory illness within the past 2 weeks Patients suspected of or at risk for neoplastic lung disease who are undergoing a bronchoscopy in which differential diagnostic considerations may include multiple other etiologies such as infection and other processes.\n  * Patients without dysplasia will be: patients undergoing clinically indicated bronchoscopy for conditions other than suspected lung cancer.\n\nPATIENT CHARACTERISTICS:\n\n* No clinically apparent bleeding diathesis\n* No known bleeding disorder\n* No anginal\n* No clinically active coronary artery disease\n* No multifocal premature ventricular contractions\n* No poorly controlled congestive heart failure\n* No myocardial infarction within the past 6 weeks\n* No cardiac dysrhythmia that is potentially life threatening\n* Well-controlled atrial fibrillation or rare (\\\u003C 2\u002Fmin) premature ventricular contractions allowed\n* No ventricular tachycardia or supraventricular tachycardia with a rapid ventricular response\n* No other serious medical condition that would preclude a patient from undergoing a bronchoscopy\n* No acute bronchitis or pneumonia within the past 8 weeks except when clinically proven as a possible result of lung cancer\n* No hypoxemia (i.e., \\\u003C 90% saturation with supplemental oxygen) before bronchoscopy\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics","ALL","21 Years","90 Years",{"count":65,"type":66},700,"ESTIMATED","OBSERVATIONAL","RATIONALE: Studying samples of sputum and tissue in the laboratory from patients with dysplasia or cancer may help doctors identify and learn more about biomarkers related to cancer. It may also help the study of cancer in the future.\n\nPURPOSE: This laboratory study is looking at biomarkers in patients with respiratory tract dysplasia or lung cancer, head and neck cancer, or aerodigestive tract cancer.",[70,71,72,73],"Esophageal Cancer","Head and Neck Cancer","Lung Cancer","Precancerous Condition",[75,76,77,78,79,80,81,82,83,84,85,86,87,88],"non-small cell lung cancer","small cell lung cancer","squamous lung dysplasia","hypopharyngeal cancer","laryngeal cancer","lip and oral cavity cancer","metastatic squamous neck cancer with occult primary","nasopharyngeal cancer","oropharyngeal cancer","paranasal sinus and nasal cavity cancer","salivary gland cancer","esophageal cancer","pulmonary carcinoid tumor","tongue cancer","2025-09-16",{"date":91,"type":92},"2025-09-22","ACTUAL",{"date":94,"type":92},"2001-05-03",{"date":96,"type":66},"2027-09-30",{"name":5,"class":6},1]